-+ 0.00%
-+ 0.00%
-+ 0.00%

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Barchart·08/11/2026 15:05:00
Listen to the news

Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201

Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.